Clearmind Medicine (NASDAQ:CMND) Posts Earnings Results

Clearmind Medicine (NASDAQ:CMND) posted its quarterly earnings results on Thursday. The company reported ($0.24) EPS for the quarter, Zacks reports.

Clearmind Medicine Stock Up 0.9 %

NASDAQ:CMND opened at $1.14 on Friday. The firm has a market cap of $4.86 million, a PE ratio of -0.61 and a beta of 1.02. The company has a 50-day moving average of $1.35 and a 200 day moving average of $1.36. Clearmind Medicine has a 1-year low of $0.95 and a 1-year high of $2.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.72 and a quick ratio of 1.72.

Clearmind Medicine Company Profile

Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.